Cardiff Oncology (CRDF) Proxy filing summary

Executive summary

• Special Meeting scheduled for October 2026 to vote on two key proposals regarding capital structure and meeting adjournment.

• Board recommends approval of both proposals to increase authorized shares and allow adjournment if needed.

• Proxy materials are available online, and shareholders are encouraged to vote by internet or mail for convenience.

Voting matters and shareholder proposals

• Proposal 1 seeks to amend the Certificate of Incorporation to increase authorized capital stock from 170M to 320M and common stock from 150M to 300M.

• Proposal 2 allows adjournment of the meeting to solicit more proxies if Proposal 1 lacks sufficient votes.

• Both proposals require a majority of shares present in person or by proxy to pass.

• Board recommends voting "FOR" both proposals.

• No appraisal rights are available for these matters.

Board of directors and corporate governance

• Board approved the proposed amendment on August 12, 2026.

• Board and executive officers have an interest in both proposals.

• Board retains discretion to abandon the amendment if deemed not in the best interests of the company.